Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filings
MORE TOOLS
WatchlistEarnings calendarGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View ORIC insider activity ↗

ORICOric Pharmaceuticals, Inc.

THE LATEST REPORTED YEAR

The company reported a loss.

$129.47M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

RevenueUnavailableNo supported USD fact
Profit or loss-$129.47MYear ended December 31, 2025
Cash from the business-$110.97MYear ended December 31, 2025
Total assets$404.69MAs of June 30, 2026
Total liabilities$23.43MAs of June 30, 2026
Cash & equivalents$37.48MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

This company does not report a supported USD concept for this metric.

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: Unavailable · Retrieved October 13, 2026

Response SHA-256: c871f4ae99434ca4e77917ac2fb9c7474f96a5b445a13c046620f15c44d1f0e6

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.